678 related articles for article (PubMed ID: 31302061)
21. The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group.
Franzese C; Marvaso G; Francolini G; Borghetti P; Trodella LE; Sepulcri M; Matrone F; Nicosia L; Timon G; Ognibene L; Vinciguerra A; Alongi F; Bortolus R; Corti L; Ramella S; Magrini SM; Livi L; Jereczek-Fossa BA; Scorsetti M; Arcangeli S
Clin Exp Metastasis; 2021 Dec; 38(6):527-537. PubMed ID: 34748125
[TBL] [Abstract][Full Text] [Related]
22. The Reintroduction of Radiotherapy Into the Integrated Management of Kidney Cancer.
Dohopolski M; Hannan R; Wardak Z; Hammers H; Garant A
Cancer J; 2020; 26(5):448-459. PubMed ID: 32947313
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
Hannan R; McLaughlin MF; Pop LM; Pedrosa I; Kapur P; Garant A; Ahn C; Christie A; Zhu J; Wang T; Robles L; Durakoglugil D; Woldu S; Margulis V; Gahan J; Brugarolas J; Timmerman R; Cadeddu J
Eur Urol; 2023 Sep; 84(3):275-286. PubMed ID: 36898872
[TBL] [Abstract][Full Text] [Related]
24. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
Siva S; Louie AV; Warner A; Muacevic A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh B; Correa RJ; Lo SS; Staehler M
Cancer; 2018 Mar; 124(5):934-942. PubMed ID: 29266183
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.
Siva S; Bressel M; Wood ST; Shaw MG; Loi S; Sandhu SK; Tran B; A Azad A; Lewin JH; Cuff KE; Liu HY; Moon D; Goad J; Wong LM; LimJoon M; Mooi J; Chander S; Murphy DG; Lawrentschuk N; Pryor D
Eur Urol; 2022 Apr; 81(4):364-372. PubMed ID: 34953600
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes.
Shanker MD; Moodaley P; Soon W; Liu HY; Lee YY; Pryor DI
J Med Imaging Radiat Oncol; 2021 Dec; 65(7):956-968. PubMed ID: 34396706
[TBL] [Abstract][Full Text] [Related]
27. Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer).
Lesueur P; Lequesne J; Barraux V; Kao W; Geffrelot J; Grellard JM; Habrand JL; Emery E; Marie B; Thariat J; Stefan D
Radiat Oncol; 2018 Jul; 13(1):138. PubMed ID: 30055640
[TBL] [Abstract][Full Text] [Related]
28. A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma.
Svedman C; Sandström P; Pisa P; Blomgren H; Lax I; Kälkner KM; Nilsson S; Wersäll P
Acta Oncol; 2006; 45(7):870-5. PubMed ID: 16982552
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
31. Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma.
Franzese C; Franceschini D; Di Brina L; DʼAgostino GR; Navarria P; Comito T; Mancosu P; Tomatis S; Scorsetti M
J Urol; 2019 Jan; 201(1):70-75. PubMed ID: 30577391
[TBL] [Abstract][Full Text] [Related]
32. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control.
Sheehan JP; Sun MH; Kondziolka D; Flickinger J; Lunsford LD
J Neurosurg; 2003 Feb; 98(2):342-9. PubMed ID: 12593621
[TBL] [Abstract][Full Text] [Related]
33. Hypofractionated Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Tumours in Children and Young Adults.
Chandy E; Taylor H; Gaito S; Wells E; Jones C; Meehan C; Burland H; Stone J; Snowball C; Mashru J; Riddell C; Hon Y; Welsh L; Saran F; Mandeville H
Clin Oncol (R Coll Radiol); 2020 May; 32(5):316-326. PubMed ID: 31813663
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic radiosurgery boost to the resection bed for oligometastatic brain disease: challenging the tradition of adjuvant whole-brain radiotherapy.
Karlovits BJ; Quigley MR; Karlovits SM; Miller L; Johnson M; Gayou O; Fuhrer R
Neurosurg Focus; 2009 Dec; 27(6):E7. PubMed ID: 19951060
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group.
Meyer E; Pasquier D; Bernadou G; Calais G; Maroun P; Bossi A; Theodore C; Albiges L; Stefan D; de Crevoisier R; Hennequin C; Lagrange JL; Grellard JM; Clarisse B; Licaj I; Habrand JL; Carrie C; Joly F
Eur J Cancer; 2018 Jul; 98():38-47. PubMed ID: 29864737
[TBL] [Abstract][Full Text] [Related]
36. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
[TBL] [Abstract][Full Text] [Related]
37. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.
Connor MJ; Smith A; Miah S; Shah TT; Winkler M; Khoo V; Ahmed HU
Eur Urol Oncol; 2020 Oct; 3(5):582-593. PubMed ID: 32891600
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of stereotactic radiotherapy for metastases from renal cell carcinoma.
Majewski W; Tabor M; Banaszek P; Glowacki G; Rokicki W; Tukiendorf A
Neoplasma; 2016; 63(1):99-106. PubMed ID: 26639239
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma.
Ranck MC; Golden DW; Corbin KS; Hasselle MD; Liauw SL; Stadler WM; Hahn OM; Weichselbaum RR; Salama JK
Am J Clin Oncol; 2013 Dec; 36(6):589-95. PubMed ID: 22868242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
